Skip to main content
. 2020 Apr 29;21(9):3145. doi: 10.3390/ijms21093145

Figure 2.

Figure 2

BJ-3105 blocked IL-6- or E. coli BW25113-induced AMPK inhibition and upregulations of cytokines and inflammasome better than tofacitinib in HT-29 cells. (a,b) Immunoblots (a) and quantitation (b) of IL-6-induced phosphorylation of JAK, STAT, and AMPK, and expressions of inflammatory cytokines. * p < 0.05, versus the vehicle-treated control group. #p < 0.05, versus the IL-6-treated group. &p < 0.05, versus the tofacitinib-treated group. (c,d) HT-29 cells were prereated with BJ-3105 or tofacitinib for 1 h prior to commensal bacteria (E. coli strain BW25113) for 3 h. After HT-29 cells were washed three times with PBS to remove non-adhering E. coli, the cells were used for immunoblotting. Immunoblots (c) of AMPK and inflammasome components, and their quantitation (d). Results are presented as the means ± SEMs of at least three independent experiments. *p < 0.05, versus the vehicle-treated control group. #p < 0.05, versus the BW25113-treated group. &p < 0.05, versus the tofacitinib-treated group.